Mallinckrodt plc To Report Third Quarter Fiscal 2015 Results On August 4, 2015

CHESTERFIELD, U.K., July 7, 2015 /PRNewswire/ -- Mallinckrodt plc (NYSE: MNK) will report third quarter fiscal 2015 results on Tuesday, August 4, 2015. A conference call for investors will begin at 8:30 a.m. U.S. Eastern time.

The call can be accessed in three ways:

• At the Mallinckrodt website: http://www.mallinckrodt.com/investors.
• By telephone: For both listen-only participants and those who wish to take part in the question-and-answer portion of the call, the telephone dial-in number in the U.S. is (877) 359-9508. For participants outside the U.S., the dial-in number is (224) 357-2393. Callers will need to provide the Conference ID of 76072223.
• Through an audio replay: A replay of the call will be available beginning at 1:30 p.m.  U.S. Eastern time on Tuesday, August 4, 2015, and ending at 11:59 p.m. U.S. Eastern Time on Tuesday, August 11, 2015. Dial-in numbers for U.S.-based participants are (855) 859-2056 or (800) 585-8367. Participants outside the U.S. should use the replay dial-in number (404) 537-3406. All callers will be required to provide the Conference ID of 76072223.

ABOUT MALLINCKRODTMallinckrodt is a global specialty biopharmaceutical and medical imaging business that develops, manufactures, markets and distributes specialty pharmaceutical products and medical imaging agents. Areas of focus include therapeutic drugs for autoimmune and rare disease specialty areas like neurology, rheumatology, nephrology and pulmonology; neonatal critical care respiratory therapies; and analgesics and central nervous system drugs for prescribing by office- and hospital-based physicians. The company's core strengths include the acquisition and management of highly regulated raw materials; deep regulatory expertise; and specialized chemistry, formulation and manufacturing capabilities. The company's Specialty Brands segment includes branded medicines; its Specialty Generics segment includes specialty generic drugs, active pharmaceutical ingredients and external manufacturing; and the Global Medical Imaging segment includes contrast media and nuclear imaging agents. To learn more about Mallinckrodt, visit www.mallinckrodt.com.

CONTACTS

Investor Relations Coleman N. Lannum, CFA Senior Vice President, Investor Strategy and IRO314-654-6649[email protected]  

John MotenVice President, Investor Relations314-654-6650[email protected]

MediaRhonda SciarraCommunications Manager314-654-8618[email protected]

Meredith FischerSenior Vice President, Communications and Public Affairs314-654-3318 [email protected]

Logo - http://photos.prnewswire.com/prnh/20150105/167103LOGO

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/mallinckrodt-plc-to-report-third-quarter-fiscal-2015-results-on-august-4-2015-300109363.html

SOURCE Mallinckrodt plc